Good evening :)
$
₹
Celldex Therapeutics Inc

Celldex Therapeutics Inc

CLDX

NASDAQ
Asset Logo

Celldex Therapeutics Inc

CLDX

NASDAQ
$29.400.52% (+0.15)
$
₹
$29.400.52% (+0.15)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.3B the stock is ranked 2057

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.68
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.35
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 15 analysts reports

Buy
14 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+115.63%

Earnings Growth

-6.01%

Rev. Growth

+23.33%

See Detailed Forecast

Company Profile

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 115.63% growth, versus a trailing 3-year CAGR of 6.35%.

2026
Current$29.25Baseline
Analyst Target - 1 year
Target$63.07+115.63%

All values in $

202220232024202520262027$34.40$46.06$57.72Target+115.63%
2026
Current$29.25Baseline
Analyst Target - 1 year
Target$63.07+115.63%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 23.33% growth, versus a trailing 3-year CAGR of -13.98%.

2025
Current$1.5Baseline
Forecast for Dec 2026
High$6.5+333.33%
Average$1.84+23.33%
Low$0-100%

All values in $ Million

2021202220232024202520264.652.356.887.021.5Low-100%Average+23.33%High+333.33%
2025
Current$1.5Baseline
Forecast for Dec 2026
High$6.5+333.33%
Average$1.84+23.33%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.89Baseline
Forecast for Dec 2026
High$-3.71+4.63%
Average$-4.12-6.01%
Low$-4.33-11.44%

All values in $

202120222023202420252026-1.56-2.21-2.91-2.45-3.89Low-11.44%Average-6.01%High+4.63%
2025
Current$-3.89Baseline
Forecast for Dec 2026
High$-3.71+4.63%
Average$-4.12-6.01%
Low$-4.33-11.44%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-67
0
-81.3
0
-78.6
0
-73.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.152.493.191.170.690.7300.070.010.02
Net Income-32.80-35.84-42.12-47.09-53.79-56.6-67.04-81.36-78.68-73.50
Net Profit Margin-21030.76%-1434.82%-1319.99%-4007.82%-7740.43%-7753.42%--108480%-524566.66%-334104.54%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Celldex Therapeutics Inc -3.680
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CLDX with any stock or ETF
Compare CLDX with any stock or ETF
Comparing from
CLDX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Celldex Therapeutics Inc (CLDX) share price today is $29.40 as of October 26, 2026 at 11:14 PM IST. The stock touched a day high of $29.64 and a day low of $28.98.

  2. Celldex Therapeutics Inc stock trades on NASDAQ under the ticker symbol CLDX.

  3. Celldex Therapeutics Inc's market capitalization is $2.29B as of October 26, 2026 at 11:14 PM IST.

  4. Celldex Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Celldex Therapeutics Inc's price-to-book (P/B) ratio is 3.68 as of October 26, 2026.

  6. Yes, You can buy Celldex Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Celldex Therapeutics Inc shares in three steps: 1. Search Celldex Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Celldex Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Celldex Therapeutics Inc (CLDX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.34 shares at the current price of $29.40.

Loading...